1. Withers HR. The four R’s of radiotherapy. In: Lett JT, Adler H, editors. Advances in radiation biology, vol. 5. New York: Academic Press; 1975. p. 241–71.
2. Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine: pharmacology and clinical studies. Amer J Physiol Imaging. 1986;1:96–103.
3. Wahl RL. Tositumomab and (131)I therapy in non-Hodgkin’s lymphoma. J Nucl Med. 2005;46 Suppl 1:128S–40.
4. Borghaei H, Wallace SG, Schilder RJ. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin’s lymphoma. Clin Lymphoma. 2004;5 Suppl 1:S16–21.
5. Larson SM, Krenning EP. A pragmatic perspective on molecular targeted radionuclide therapy. J Nucl Med. 2005;46 Suppl 1:1S–3.